Is Cedar profitable in 2026?

No public profitability data exists. Third-party estimates put 2023 revenue near $102.1 million (Getlatka, 2025-11-27), and Cedar has not confirmed a new primary funding round since December 2022, suggesting cash discipline rather than confirmed profitability.

Could AI replace Cedar's business?

Unlikely soon. Cedar's Kora voice agent, launched April 2025, runs on Cedar's own proprietary dataset of over a billion patient interactions and 200+ EHR/payer integrations, a data and workflow moat generic AI vendors cannot easily replicate as of June 2026.

Who is Cedar's biggest competitor?

Waystar, public since 2024 with about $1.1 billion FY2025 revenue (+17% YoY), and Experian Health (~$1.2 billion 2023 revenue) are both actively adding patient-pay AI features that compete directly with Cedar's Kora and Cedar Pay products.

Who owns Cedar the healthcare payments company?

Cedar is privately held and venture-backed, founded in 2016 by Florian Otto, Arel Lidow, and Kareem Zaki, with investors including Tiger Global, a16z, Founders Fund, and Memorial Hermann Foundation; no parent company controls it as of 2026.

Cedar's most recently disclosed valuation is $3.2 billion, set in March 2021 during a $200 million Series D led by Tiger Global. No confirmed new primary valuation has been reported as of mid-2026, a roughly 5-year gap.

Has Cedar had layoffs?

Yes. Cedar cut 24% of its workforce, about 127 employees, in July 2022 during the digital-health funding downturn. No further Cedar-specific layoffs were found in 2025-2026 reporting as of June 2026.

AI companies and labs · United States

Cedar

cedar.com ↗

Cedar builds AI-driven patient billing and payment software for hospitals and health systems.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Waystar or Epic could ship a competitive AI billing agent that slows Cedar's health system signups

The call

Cedar has real AI traction and sticky hospital contracts, but bigger billing companies are building the same tools and no fresh funding round has confirmed its valuation in years.

Cedar built Kora, an AI tool that helps hospitals collect money from patients faster and more accurately. The company has real evidence it works across 55+ hospitals and has learned from over 1 billion patient records, which is hard for others to replicate quickly. However, Waystar (which went public in 2024) and Experian Health, both much larger billing software companies, are already building the same AI features into their own products. Cedar stays ahead because it got there first and its software is deeply woven into hospital systems, but there is no law or technology stopping these bigger companies from catching up. The critical question is whether Cedar can keep winning new hospital customers faster than Waystar and Experian can convince existing customers that the rivals' version works just as well.

Why

AI pressure: None apparent. Generic AI chatbots can't touch patient billing without health system integrations, so Cedar's own AI, Kora, is the product, not the threat. Could AI do the core job? Unlikely.

Bigger players: Waystar and Experian Health. Both are bundling AI billing tools into their bigger revenue cycle platforms, aiming to copy what Kora already does. Could a giant copy it? Probably.

What protects it. Deep EHR and payer integrations plus 1 billion+ patient interactions make Cedar hard to rip out once installed.

What would change this call

Waystar or Experian Health announces a Kora-like AI billing/voice agent in their RCM suite. Shows incumbents are closing Cedar's product lead rather than just chasing it.
Cedar announces a new primary funding round or updated valuation after Dec 2022. Confirms investors still back Cedar's moat at or above its $3.2B mark.
Cedar reports net-new health-system signings or losses to Waystar/Experian in 2026-2027. Indicates whether Cedar is gaining or losing share against bundled RCM incumbents.

Key numbers

50M+ patients served, $10B+ payments processed (2025-2026)
Kora handled 400,000 calls across 10 providers (2026-06)
No new primary funding round since Dec 2022 (2026-06)

Named risks

No confirmed new primary funding round since December 2022, leaving valuation stale at $3.2B since March 2021. Severity: medium
Larger incumbents Waystar and Experian Health are shipping comparable AI patient-pay features with far larger revenue bases. Severity: high
Growth strategy tied to Medicaid policy volatility (One Big Beautiful Bill Act) could shift rapidly with legislation. Severity: medium
Kora's agentic outbound expansion unproven beyond 10 pilot provider organizations as of June 2026. Severity: medium
Prior 24% workforce reduction in July 2022 signals historical financial stress under funding downturns. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Waystar	contesting	Public since 2024, $1.1B FY2025 revenue (+17% YoY), bundling patient-pay AI into RCM deals
Experian Health	contesting	~$1.2B 2023 revenue, adding AI billing/estimation features similar to Cedar's
Epic/Cerner (Oracle Health)	gaining on	Own in-house billing modules, not structurally barred from shipping AI billing layer
Phreesia	contesting	Public patient intake/pre-visit payment competitor, ~$356M 2024 revenue

Questions people ask

Is Cedar profitable in 2026?: No public profitability data exists. Third-party estimates put 2023 revenue near $102.1 million (Getlatka, 2025-11-27), and Cedar has not confirmed a new primary funding round since December 2022, suggesting cash discipline rather than confirmed profitability.
Could AI replace Cedar's business?: Unlikely soon. Cedar's Kora voice agent, launched April 2025, runs on Cedar's own proprietary dataset of over a billion patient interactions and 200+ EHR/payer integrations, a data and workflow moat generic AI vendors cannot easily replicate as of June 2026.
Who is Cedar's biggest competitor?: Waystar, public since 2024 with about $1.1 billion FY2025 revenue (+17% YoY), and Experian Health (~$1.2 billion 2023 revenue) are both actively adding patient-pay AI features that compete directly with Cedar's Kora and Cedar Pay products.
Who owns Cedar the healthcare payments company?: Cedar is privately held and venture-backed, founded in 2016 by Florian Otto, Arel Lidow, and Kareem Zaki, with investors including Tiger Global, a16z, Founders Fund, and Memorial Hermann Foundation; no parent company controls it as of 2026.
What is Cedar worth?: Cedar's most recently disclosed valuation is $3.2 billion, set in March 2021 during a $200 million Series D led by Tiger Global. No confirmed new primary valuation has been reported as of mid-2026, a roughly 5-year gap.
Has Cedar had layoffs?: Yes. Cedar cut 24% of its workforce, about 127 employees, in July 2022 during the digital-health funding downturn. No further Cedar-specific layoffs were found in 2025-2026 reporting as of June 2026.

Timeline

2026-06-15Kora AI voice agent hits ~400,000 patient calls, adopted by 10 provider organizations
2026-04-07Cedar Intelligence expands to 80+ patient attributes; launches Kora Outbound
2026-03-24Cedar reports 3x ROI and 83% self-service rate among athenaOne physician-group partners
2025-10-20Cedar launches Cedar Cover, a Medicaid/affordability digital safety-net product
2025-04-29Cedar rolls out Kora, its AI voice agent for billing calls, built with Twilio
2022-12Series D extension of $68.4M led by Memorial Hermann Foundation
2022-07Cedar lays off 24% of workforce (~127 people)
2021-03-09Cedar closes $200M Series D led by Tiger Global at $3.2B valuation
2020-06Cedar raises $102M Series C led by a16z at $427M valuation
2016Cedar founded by Florian Otto, Arel Lidow, and Kareem Zaki; raises $13M Series A

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere